Loading
A phase 2 trial of pCAR-19B cells in acute lymphoblastic leukaemia and childhood cancers, run by Chongqing Precision Biotech Co., Ltd, now recruiting.
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents is a phase 2 interventional study registered as NCT05334823 by Chongqing Precision Biotech Co., Ltd, with 100 participants planned, started 2022-01-26 and due to reach its primary completion in 2028-12-31. Interventions recorded: pCAR-19B cells.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chongqing Precision Biotech and the tag pipeline.
Shares Chongqing Precision Biotech and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/